Manso, M., Alexandre, B., Antunes-Lopes, T., Martins-da-Silva, C., & Cruz, F. (2017). Is the adjustable transobturator system ATOMS® useful for the treatment of male urinary incontinence in low to medium volume urological centers?. Actas Urologicas Espanolas.

Antunes-Lopes, T., Coelho, A., Pinto, R., Barros, S. C., et al. (2017). Author Reply. Urology, 99, 55 - 56.

Coelho, A., Antunes-Lopes, T., Gillespie, J., & Cruz, F. (2017). Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study. Neurourology and Urodynamics, 36(8), 1972 - 1980.

Chapple, C. R., Cruz, F., Deffieux, X., Milani, A. L., et al. (2017). Consensus Statement of the European Urology Association and the European Urogynaecological Association on the Use of Implanted Materials for Treating Pelvic Organ Prolapse and Stress Urinary Incontinence. European Urology, 72(3), 424 - 431.

Kennelly, M., Dmochowski, R., Schulte-Baukloh, H., Ethans, K., et al. (2017). Efficacy and safety of onabotulinumtoxinA therapy are sustained over 4 years of treatment in patients with neurogenic detrusor overactivity: Final results of a long-term extension study. Neurourology and Urodynamics, 36(2), 368 - 375.

Oliveira, R., Coelho, A., Charrua, A., Avelino, A., & Cruz, F. (2017). Expression of cleaved SNAP-25 after bladder wall injection of onabotulinumtoxina or abobotulinumtoxina: A comparative study in the mice. Neurourology and Urodynamics, 36(1), 86 - 90.

Antunes-Lopes, T., Coelho, A., Pinto, R., Barros, S. C., et al. (2017). Urinary Neurotrophin Levels Increase in Women With Stress Urinary Incontinence After a Midurethral Sling Procedure. Urology, 99, 49 - 56.

Matos, R., Serrão, P., Rodriguez, L., Birder, L. A., et al. (2017). The water avoidance stress induces bladder pain due to a prolonged alpha1A adrenoceptor stimulation. Naunyn-Schmiedeberg's Archives of Pharmacology, 390(8), 839 - 844.

Avelino, A., Cruz, F., Panicker, J. N., & Liechti, M. D. (2016). Basic principles. In Practical Functional Urology (pp. 1 - 17).

Matos, R., Cordeiro, J. M., Coelho, A., Ferreira, S., et al. (2016). Bladder pain induced by prolonged peripheral alpha 1A adrenoceptor stimulation involves the enhancement of transient receptor potential vanilloid 1 activity and an increase of urothelial adenosine triphosphate release. Acta Physiologica, 218(4), 265 - 275.

De Carvalho, T. G. R., Pinto, R., Cruz, F., & Silva, J. (2016). Effect of onabotulinum toxin type a intraprostatic injection on the outcome of benign prostatic hyperplasia patients refractory to medical therapy: A 2-year follow-up study. Archivos Espanoles de Urologia, 69(10), 719 - 726.

Montorsi, F., Gandaglia, G., Chapple, C., Cruz, F., et al. (2016). Effectiveness and safety of silodosin in the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia: A European phase IV clinical study (SiRE study). International Journal of Urology, 23(7), 572 - 579.

Martins-Silva, C., & Cruz, F. (2016). Efficacy and Safety of OnabotulinumtoxinA in Patients with Urinary Incontinence Due to Neurogenic Detrusor Overactivity: Update of the Pivotal Randomised, Double-blind, Placebo-controlled Trials. European Urology Focus, 2(3), 329 - 331.

Antunes-Lopes, T., C. da Silva, M., & Cruz, F. (2016). Evaluation of the Donor After Brain Death and Technique for Organ Procurement. European Urology, Supplements, 15(9), 390 - 396.

Coelho, A., Oliveira, R., Cruz, F., & Cruz, C. D. (2016). Impairment of sensory afferents by intrathecal administration of botulinum toxin A improves neurogenic detrusor overactivity in chronic spinal cord injured rats. Experimental Neurology, 285, 159 - 166.

Cruz, F. (2016). Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE). European Urology, 70(5), 892.

Cruz, C. D., Coelho, A., Antunes-Lopes, T., & Cruz, F. (2015). Biomarkers of spinal cord injury and ensuing bladder dysfunction. Advanced Drug Delivery Reviews, 82, 153 - 159.

Laterza, R. M., Sievert, K. - D., de Ridder, D., Vierhout, M. E., et al. (2015). Bladder function after radical hysterectomy for cervical cancer. Neurourology and Urodynamics, 34(4), 309 - 315.

Charrua, A., Pinto, R., Taylor, A., Canelas, A., et al. (2015). Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourology and Urodynamics, 34(5), 489 - 496.

Charrua, A., Cruz, C. D., Jansen, D., Rozenberg, B., et al. (2015). Co-administration of transient receptor potential vanilloid 4 (TRPV4) and TRPV1 antagonists potentiate the effect of each drug in a rat model of cystitis. BJU International, 115(3), 452 - 460.

Dinis, S., De Oliveira, J. T., Pinto, R., Cruz, F., et al. (2015). From bladder to systemic syndrome: Concept and treatment evolution of interstitial cystitis. International Journal of Women's Health, 7, 735 - 744.

Charrua, A., & Cruz, F. (2015). Intravesical Capsaicin and Resiniferatoxin for Bladder Disorders. In TRP Channels as Therapeutic Targets: From Basic Science to Clinical Use (pp. 119 - 127).

Frias, B., Santos, J., Morgado, M., Sousa, M. M., et al. (2015). The role of brain-derived neurotrophic factor (BDNF) in the development of neurogenic detrusor overactivity (NDO). Journal of Neuroscience, 35(5), 2146 - 2160.

Bunn, F., Kirby, M., Pinkney, E., Cardozo, L., et al. (2015). Is there a link between overactive bladder and the metabolic syndrome in women? A systematic review of observational studies. International Journal of Clinical Practice, 69(2), 199 - 217.

Coelho, A., Wolf-Johnston, A. S., Shinde, S., Cruz, C. D., et al. (2015). Urinary bladder inflammation induces changes in urothelial nerve growth factor and TRPV1 channels. British Journal of Pharmacology.

Coelho, A., Wolf-Johnston, A. S., Shinde, S., Cruz, C. D., et al. (2015). Urinary bladder inflammation induces changes in urothelial nerve growth factor and TRPV1 channels. British Journal of Pharmacology, 172(7), 1691 - 1699.

Silva, J., Silva, C. M., & Cruz, F. (2014). Current medical treatment of lower urinary tract symptoms/BPH: Do we have a standard?. Current Opinion in Urology, 24(1), 21 - 28.

Frias, B., Allen, S., Dawbarn, D., Charrua, A., et al. (2013). Brain-derived neurotrophic factor, acting at the spinal cord level, participates in bladder hyperactivity and referred pain during chronic bladder inflammation. Neuroscience, 234, 88 - 102.

Tomada, N., Tomada, I., Botelho, F., Pacheco-Figueiredo, L., et al. (2013). Endothelial function in patients with metabolic syndrome and erectile dysfunction: A question of Angiopoietin imbalance?. Andrology, 1(4), 541 - 548.

Pinto, R., Lopes, T., Silva, J., Silva, C., et al. (2013). Persistent therapeutic effect of repeated injections of onabotulinum toxin A in refractory bladder pain syndrome/interstitial cystitis. Journal of Urology, 189(2), 548 - 553.

Avelino, A., Charrua, A., Frias, B., Cruz, C., et al. (2013). Transient receptor potential channels in bladder function. Acta Physiologica, 207(1), 110 - 122.

Antunes-Lopes, T., Pinto, R., Barros, S. C., Botelho, F., et al. (2013). Urinary neurotrophic factors in healthy individuals and patients with overactive bladder. Journal of Urology, 189(1), 359 - 365.

Gorgal, T., Charrua, A., Silva, J. F., Avelino, A., et al. (2012). Expression of apoptosis-regulating genes in the rat prostate following botulinum toxin type a injection. BMC Urology, 12.

Santos-Silva, A., Charrua, A., Cruz, C. D., Gharat, L., et al. (2012). Rat detrusor overactivity induced by chronic spinalization can be abolished by a transient receptor potential vanilloid 1 (TRPV1) antagonist. Autonomic Neuroscience: Basic and Clinical, 166(1-2), 35 - 38.

Coelho, A., Cruz, F., Cruz, C. D., & Avelino, A. (2012). Reply from Authors re: Prokar Dasgupta. Volume matters: Bladder injections of botulinum toxin type A. Eur Urol 2012;61:1185-6: Yes, Volume matters: Bladder injections of botulinum toxin type A. European Urology, 61(6), 1186 - 1187.

Coelho, A., Cruz, F., Cruz, C. D., & Avelino, A. (2012). Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. European Urology, 61(6), 1178 - 1184.

Frias, B., Charrua, A., Avelino, A., Michel, M. C., et al. (2012). Transient receptor potential vanilloid 1 mediates nerve growth factor-induced bladder hyperactivity and noxious input. BJU International.

Tomada, N., Tomada, I., Botelho, F., Cruz, F., & Vendeira, P. (2011). Are all metabolic syndrome components responsible for penile hemodynamics impairment in patients with erectile dysfunction? The role of body fat mass assessment. Journal of Sexual Medicine, 8(3), 831 - 839.

Antunes-Lopes, T., Carvalho-Barros, S., Cruz, C. - D., Cruz, F., & Martins-Silva, C. (2011). Biomarkers in overactive bladder: A new objective and noninvasive tool?. Advances in Urology.

Cruz, F., Herschorn, S., Aliotta, P., Brin, M., et al. (2011). Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: A randomised, double-blind, placebo-controlled trial. European Urology, 60(4), 742 - 750.

Oliveira, R., Botelho, F., Silva, P., Resende, A., et al. (2011). Exploratory study assessing efficacy and complications of TVT-O, TVT-Secur, and Mini-Arc: Results at 12-month follow-up. European Urology, 59(6), 940 - 944.

Silva, J., Pinto, R., Carvalho, T., Botelho, F., et al. (2011). Intraprostatic botulinum toxin type A administration: Evaluation of the effects on sexual function. BJU International, 107(12), 1950 - 1954.

Athanasopoulos, A., & Cruz, F. (2011). The medical treatment of overactive bladder, including current and future treatments. Expert Opinion on Pharmacotherapy, 12(7), 1041 - 1055.

Charrua, A., Avelino, A., & Cruz, F. (2011). Modulation of urinary bladder innervation: TRPV1 and botulinum toxin A. Handbook of Experimental Pharmacology (Vol. 202, pp. 345 - 374).

Oliveira, R., Botelho, F., Silva, P., Resende, A., et al. (2011). Reply from authors re: Elisabetta costantini and massimo lazzeri. Surgery for stress urinary incontinence: So near and yet so far. Eur Urol 2011;59:945-6. European Urology, 59(6), 947.

Oliveira, R., Botelho, F., Silva, P., Resende, A., et al. (2011). Single-incision sling system as primary treatment of female stress urinary incontinence: Prospective 12 months data from a single institution. BJU International, 108(10), 1616 - 1621.

Cruz, C. D., & Cruz, F. (2011). Spinal cord injury and bladder dysfunction: New ideas about an old problem. TheScientificWorldJournal, 11, 214 - 234.

Oliveira, R., Silva, C., Dinis, P., & Cruz, F. (2011). Suburethral single incision slings in the treatment of female stress urinary incontinence: What is the evidence for using them in 2010?. Archivos Espanoles de Urologia, 64(4), 339 - 346.

Saban, M. R., Davis, C. A., Avelino, A., Cruz, F., et al. (2011). VEGF signaling mediates bladder neuroplasticity and inflammation in response to BCG. BMC Physiology, 11(1).

Tomada, N., Tomada, I., Cruz, F., Vendeira, P., & Neves, D. (2010). Characterization of VEGF and angiopoietins expression in human corpus cavernosum during aging. Journal of Sexual Medicine, 7(4 PART 1), 1410 - 1418.

Coelho, A., Dinis, P., Pinto, R., Gorgal, T., et al. (2010). Distribution of the High-Affinity Binding Site and Intracellular Target of Botulinum Toxin Type A in the Human Bladder. European Urology, 57(5), 884 - 890.

Cruz, F., & Desgrandchamps, F. (2010). New Concepts and Pathophysiology of Lower Urinary Tract Symptoms in Men. European Urology, Supplements, 9(4), 472 - 476.

Pinto, R., Frias, B., Allen, S., Dawbarn, D., et al. (2010). Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience, 166(3), 907 - 916.

Pinto, R., Lopes, T., Frias, B., Silva, A., et al. (2010). Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Journal of Urology, 184(4), 1364 - 1365.

Pinto, R., Lopes, T., Frias, B., Silva, A., et al. (2010). Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. European Urology, 58(3), 360 - 365.

Birder, L. A., Kanai, A. J., Cruz, F., Moore, K., & Fry, C. H. (2010). Is the urothelium intelligent?. Neurourology and Urodynamics, 29(4), 598 - 602.

Botelho, F., Pina, F., Silva, P., Figueiredo, G., et al. (2010). Vascular endothelial growth factor (VEGF) and prostate pathology. International Braz J Urol, 36(4), 430 - 437.

Charrua, A., Reguenga, C., Cordeiro, J. M., Correiade-Sá, P., et al. (2009). Functional Transient Receptor Potential Vanilloid 1 is Expressed in Human Urothelial Cells. Journal of Urology, 182(6), 2944 - 2950.

Charrua, A., Cruz, C. D., Narayanan, S., Gharat, L., et al. (2009). GRC-6211, a New Oral Specific TRPV1 Antagonist, Decreases Bladder Overactivity and Noxious Bladder Input in Cystitis Animal Models. Journal of Urology, 181(1), 379 - 386.

Da Silva, C. M., & Cruz, F. (2009). Has botulinum toxin therapy come of age: What do we know, what do we need to know, and should we use it?. Current Opinion in Urology, 19(4), 347 - 352.

Guimarães, M., Oliveira, R., Pinto, R., Soares, A., et al. (2009). Intermediate-term results, up to 4 years, of a bone-anchored male perineal sling for treating male stress urinary incontinence after prostate surgery. BJU International, 103(4), 500 - 504.

Silva, J., Pinto, R., Carvalho, T., Botelho, F., et al. (2009). Intraprostatic Botulinum Toxin Type A injection in patients with benign prostatic enlargement: Duration of the effect of a single treatment. BMC Urology, 9(1).

Silva, J., Pinto, R., Carvallho, T., Coelho, A., et al. (2009). Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. European Urology, 56(1), 134 - 141.

Ferreira, S. G., Lomaglio, T., Avelino, A., Cruz, F., et al. (2009). N-acyldopamines control striatal input terminals via novel ligand-gated cation channels. Neuropharmacology, 56(3), 676 - 683.

Andersson, K. - E., Chapple, C. R., Cardozo, L., Cruz, F., et al. (2009). Pharmacological treatment of overactive bladder: Report from the International Consultation on Incontinence. Current Opinion in Urology, 19(4), 380 - 394.

Cruz, F., Silva, J., Pinto, R., Carvallho, T., et al. (2009). Reply to Tomasz Drewa, Zbigniew Wolski and Janusz Tyloch's Letter to the Editor re: João Silva, Rui Pinto, Tiago Carvallho, et al. Mechanisms of Prostate Atrophy after Glandular Botulinum Neurotoxin Type A Injection: An Experimental Study in the Rat. Eur. European Urology, 56(5), e28 - e29.

Oliveira, R., Silva, A., Pinto, R., Silva, J., et al. (2009). Short-term assessment of a tension-free vaginal tape for treating female stress urinary incontinence. BJU International, 104(2), 225 - 228.

Charrua, A., Reguenga, C., Paule, C. C., Nagy, I., et al. (2008). Cystitis is associated with TRPVIb-downregulation in rat dorsal root ganglia. NeuroReport, 19(15), 1469 - 1472.

Silva, J., Silva, C., Saraiva, L., Silva, A., et al. (2008). Intraprostatic Botulinum Toxin Type A Injection in Patients Unfit for Surgery Presenting with Refractory Urinary Retention and Benign Prostatic Enlargement. Effect on Prostate Volume and Micturition Resumption. European Urology, 53(1), 153 - 159.

Cruz, C. D., Charrua, A., Vieira, E., Valente, J., et al. (2008). Intrathecal delivery of resiniferatoxin (RTX) reduces detrusor overactivity and spinal expression of TRPV1 in spinal cord injured animals. Experimental Neurology, 214(2), 301 - 308.

Cruz, C. D., Ferreira, D., McMahon, S. B., & Cruz, F. (2007). The activation of the ERK pathway contributes to the spinal c-fos expression observed after noxious bladder stimulation. Somatosensory and Motor Research, 24(1-2), 15 - 20.

Silva, C., Silva, J., Castro, H., Reis, F., et al. (2007). Bladder sensory desensitization decreases urinary urgency. BMC Urology, 7.

Cruz, C. D., & Cruz, F. (2007). The ERK 1 and 2 pathway in the nervous system: From basic aspects to possible clinical applications in pain and visceral dysfunction. Current Neuropharmacology, 5(4), 244 - 252.

Baiou, D., Santha, P., Avelino, A., Charrua, A., et al. (2007). Neurochemical characterization of insulin receptor-expressing primary sensory neurons in wild-type and vanilloid type 1 transient receptor potential receptor knockout mice. Journal of Comparative Neurology, 503(2), 334 - 347.

Cruz, F., & Dinis, P. (2007). Resiniferatoxin and botulinum toxin type A for treatment of lower urinary tract symptoms. Neurourology and Urodynamics, 26(6 SUPPL.), 920 - 927.

Charrua, A., Cruz, C. D., Cruz, F., & Avelino, A. (2007). Transient Receptor Potential Vanilloid Subfamily 1 is Essential for the Generation of Noxious Bladder Input and Bladder Overactivity in Cystitis. Journal of Urology, 177(4), 1537 - 1541.

Dickson, A., Avelino, A., Cruz, F., & Ribeiro-da-Silva, A. (2006). Peptidergic sensory and parasympathetic fiber sprouting in the mucosa of the rat urinary bladder in a chronic model of cyclophosphamide-induced cystitis. Neuroscience, 139(2), 671 - 685.

Dickson, A., Avelino, A., Cruz, F., & Ribeiro-da-Silva, A. (2006). Peptidergic sensory and parasympathetic fiber sprouting in the mucosa of the rat urinary bladder in a chronic model of cyclophosphamide-induced cystitis (DOI:10.1016/j.neuroscience.2005.11.050). Neuroscience, 141(3), 1633 - 1647.

Cruz, C. D., McMahon, S. B., & Cruz, F. (2006). Spinal ERK activation contributes to the regulation of bladder function in spinal cord injured rats. Experimental Neurology, 200(1), 66 - 73.

Szallasi, A., Cruz, F., & Geppetti, P. (2006). TRPV1: a therapeutic target for novel analgesic drugs?. Trends in Molecular Medicine, 12(11), 545 - 554.

Avelino, A., & Cruz, F. (2006). TRPV1 (vanilloid receptor) in the urinary tract: Expression, function and clinical applications. Naunyn-Schmiedeberg's Archives of Pharmacology, 373(4), 287 - 299.

Dinis, P., Charrua, A., Avelino, A., Nagy, I., et al. (2005). The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate. European Urology, 48(1), 162 - 167.

Cruz, C. D., Avelino, A., McMahon, S. B., & Cruz, F. (2005). Increased spinal cord phosphorylation of extracellular signal-regulated kinases mediates micturition overactivity in rats with chronic bladder inflammation. European Journal of Neuroscience, 21(3), 773 - 781.

Cruz, C. D., Neto, F. L., Castro-Lopes, J., McMahon, S. B., & Cruz, F. (2005). Inhibition of ERK phosphorylation decreases nociceptive behaviour in monoarthritic rats. Pain, 116(3), 411 - 419.

Silva, C., Silva, J., Ribeiro, M. - J., Avelino, A., & Cruz, F. (2005). Urodynamic effect of intravesical resiniferatoxin in patients with neurogenic detrusor overactivity of spinal origin: Results of a double-blind randomized placebo-controlled trial. European Urology, 48(4), 650 - 655.

Dinis, P., Charrua, A., Avelino, A., Yaqoob, M., et al. (2004). Anandamide-evoked activation of vanilloid receptor 1 contributes to the development of bladder hyperreflexia and nociceptive transmission to spinal dorsal horn neurons in cystitis. Journal of Neuroscience, 24(50), 11253 - 11263.

Dinis, P., Silva, J., Ribeiro, M. J., Avelino, A., et al. (2004). Bladder C-fiber desensitization induces a long-lasting improvement of BPH-associated storage LUTS: A pilot study. European Urology, 46(1), 88 - 94.

Cruz, F., & Silva, C. (2004). Botulinum toxin in the management of lower urinary tract dysfunction: Contemporary update. Current Opinion in Urology, 14(6), 329 - 334.

Dinis, P., Charrua, A., Avelino, A., & Cruz, F. (2004). Intravesical resiniferatoxin decreases spinal c-fos expression and increases bladder volume to reflex micturition in rats with chronic inflamed urinary bladders. BJU International, 94(1), 153 - 157.

Cruz, F. (2004). Mechanisms involved in new therapies for overactive bladder. Urology, 63(3 SUPPL. 1), 65 - 73.